The Scientific Frontier

Obesity Drugs

2 articles

A symbolic bridge representing Medicare's temporary copay program for obesity drugs, connecting patients to vital medications.
Cosmos & Physics

Medicare's temporary $50 copay for obesity drugs like Zepbound

Starting July 1, 2026, eligible Medicare Part D beneficiaries will access branded obesity drugs like Zepbound for a $50 monthly copay, an unprecedented expansion of coverage set to expire just 18 mont

Dr. Evelyn Reed·June 8, 2026
A scientist in a futuristic lab examining a holographic display of a triple hormone receptor drug, representing Pfizer's new obesity treatment.
Cosmos & Physics

Pfizer advances monthly obesity drug targeting triple hormone receptors

Pfizer is advancing a monthly weight-loss injection, danuglipron, having announced positive early-stage data.

Dr. Evelyn Reed·June 7, 2026